In vitro Activity of Tebipenem, an Orally Available Carbapenem Agent, against a Collection of Surveillance Gram-positive Clinical Isolates Posted on September 29, 2021 at 1:34 pm.Written by Spero Therapeutics View Presentation Post navigation EPIDEMIOLOGY AND 12-MONTH ANTIBIOTIC USE IN THE OUTPATIENT SETTING AMONG ADULT PATIENTS WITH COMPLICATED URINARY TRACT INFECTIONS: A RETROSPECTIVE DATABASE ANALYSISPharmacokinetics-Pharmacodynamics Evaluation of Tebipenem Pivoxil Hydrobromide Using the 10-Day Hollow-Fiber In Vitro Infection Model